Protective Properties of 2-Acetylcylopopentanone in a Mouse Model of Acetaminophen Hepatotoxicity

Lihai Zhang, Terrence Gavin, Brian C. Geohagen, Qiang Liu, Katherine J. Downey, Richard M. LoPachin; Department of Anesthesiology (L.Z., B.C.G. and R.M.L.), Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Department of Pathology (Q.L., K.J.D.), Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY and; Department of Chemistry (T.G.) Iona College, New Rochelle, NY
Abstract

Our previous research showed that enolates formed from 1,3-dicarbonyl compounds, such as 2-acetylcyclopentanone (2-ACP), could provide protection in cell culture models of electrophile- or oxidative stress-induced toxicity. In the present study, we evaluated the protective abilities of 2-ACP in a mouse model of acetaminophen (APAP) hepatotoxicity. Results show that oral APAP overdose (500 mg/kg) was nearly 90% lethal within 72 hrs and that the resulting hepatotoxicity was associated with substantial changes in plasma liver enzyme activities, histopathological indices and markers of hepatocyte oxidative stress. 2-ACP administered i.p. 20 minutes prior to APAP completely prevented lethality over a 7-day observation period. This effect was dose-dependent (0.80 – 2.40 mmol/kg) and was correlated with normalization of measured parameters. Nearly complete protection was afforded when 2-ACP was administered 20 minutes post-APAP, but not 60 minutes after intoxication. Although i.p. administration of N-acetylcysteine (NAC) was not effective over a broad dose-range (2.40-7.20 mmol/kg), temporal studies indicated that i.p. NAC was hepatoprotective when injected 60 min after APAP intoxication. Due to a loss of function in stomach acid, oral administration of 2-ACP was associated with modest APAP protection. In contrast, NAC administered orally provided dose-dependent (0.80 – 2.40 mmol/kg) protection against APAP hepatotoxicity. In chemico studies and quantum mechanical calculations indicated that 2-ACP acted as a surrogate nucleophile target for the reactive electrophilic APAP metabolite N-acetyl-p-benzoquinone imine (NAPQI). Our findings suggest that 2-ACP or a derivative might be useful in treating acquired toxicities associated with electrophilic drugs, metabolites or environmental toxicants.
Introduction

Recent studies (LoPachin et al., 2011) showed that enolates formed from 1,3-dicarbonyl compounds (Fig. 1A), such as acetylacetone (AcAc) and 2-acytetylcylopentanone (2-ACP), are cytoprotective in cell culture models of oxidative stress (H_2O_2) or electrophile (acrolein)-induced toxicity. The idea that these β-diketones might be cytoprotective stems from the recognition that the central heptadienone bridge of curcumin (Fig. 1A) is also a dicarbonyl compound and that, although the contributing mechanism is uncertain, the presence of this substructure is critically important for cytoprotection (Begum et al., 2008; Weber et al., 2006; see detailed discussion in LoPachin et al., 2011).

1,3-Dicarboxyls exist as equilibrating tautomers (Fig. 1B) with the enol-containing isomers generally predominating (Balasubramanian, 2006; Payton et al., 2007). In ionizing solutions such as biological buffers, loss of a proton from either the central ("α") carbon of the diketo tautomer or the enol hydroxyl group of the isomer yields a resonance stabilized nucleophilic enolate anion (Fig. 1C). Enolate sites on dicarbonyl compounds are Michael donors that can form covalent adducts with electrophiles (Awasthi et al., 1996; Bug and Mayr, 2003; Loudon, 2002). Indeed, recent studies of oxidative stress (LoPachin et al., 2011) showed that although free radical trapping was not involved, enolate-forming 1,3-dicarbonyl compounds provided cytoprotection by scavenging electrophilic α,β-unsaturated carbonyl derivatives (e.g., acrolein, 4-hydroxy-2-nonenal) that participate in the corresponding cell injury process.

The enolate of a 1,3-dicarbonyl compound can also function as a bidentate chelator of iron [Fe(III)], copper [Cu(II)] and other electrophilic metal ions (Eames, 2009; Jiao et al., 2006). In our studies of oxidative stress (LoPachin et al., 2011) we provided
evidence that the metal chelating abilities of 2-ACP and AcAc were important components of 1,3-dicarbonyl cytoprotection. Metal ion chelation can be cytoprotective by limiting the participation of iron and copper in the metal-catalyzed Fenton reaction, which reduces the generation of the highly toxic hydroxyl radical (Halliwell, 2006) and thereby blocks the oxidative stress cascade. The 1,3-dicarbonyl compounds, therefore, have at least two cytoprotective actions specifically linked to their ability to form enolate moieties; i.e., electrophile scavenging and metal ion chelation. These properties are the mechanistic basis of cytoprotection (LoPachin et al., 2011, 2012).

Our previous investigations identified 2-ACP as the most potent 1,3-dicarbonyl compound with respect to in vitro cytoprotection (LoPachin et al., 2011). However, the protective capacity of this type of compound has not been evaluated in an animal model. Therefore, in the present study we determined the ability of 2-ACP to prevent hepatotoxicity in a mouse model of acetaminophen (Tylenol®; APAP) poisoning. Experimental APAP intoxication in laboratory animals is a clinically relevant model that has been used to assess putative cytoprotectants (Jaeschke et al., 2011). Moreover, although some information gaps remain, the molecular mechanism of APAP hepatotoxicity has been investigated extensively and is relatively well understood. Specifically, in overdose, excess acetaminophen (APAP) is metabolized by the liver cytochrome P450 system to a highly reactive electrophile metabolite, N-acetyl-p-benzoquinone imine (NAPQI), which causes hepatocyte damage via glutathione (GSH) depletion, covalent modification of mitochondrial proteins and oxidative stress (Hinson et al., 2010; Jaeschke and Bajt, 2006). The primary involvement of an electrophilic metabolite and development of secondary oxidative stress suggests that APAP
intoxication in mice might be an appropriate model for testing the in vivo protective properties of 2-ACP.

**Materials and Methods**

**Reagents.** All chemicals were of the highest grade commercially available and, unless otherwise stated, were purchased from Sigma-Aldrich (St. Louis, MO). Pierce bicinchoninic acid (BCA) protein assay kits and radio-immunoprecipitation assay (RIPA) buffer were purchased from Thermo Fisher Scientific Inc. (Rockford, IL). Protease Inhibitor Cocktail was purchased from Roche (Indianapolis, IN).

**Animals and Treatments.** All aspects of animal use in this study were in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals and were approved by the Montefiore Medical Center Animal Care Committee. Three month old male C57BL/6N mice (mean weight 27gm) were purchased from Charles River Laboratory (Wilmington, MA). Mice were housed individually in polycarbonate boxes, and filtered drinking water and Purina Rodent Laboratory Chow (Purina Mills, Inc., St. Louis, MO) were available ad libitum. The animal room was maintained at approximately 22° C and 50% humidity with a 12 hr light/dark cycle. Prior to each experiment, mice were fasted overnight and treatments began at 0800 the following morning. Food was returned 1 hr post-treatment. APAP and all experimental compounds were administered in phosphate buffered polyethylene glycol. Preliminary studies demonstrated that this vehicle did not affect the experimental outcome. As a general protocol, groups of mice (n=15) were pretreated by intraperitoneal (i.p.; 10 ml/kg) injection of either 2-ACP (2.4 mmol/kg) or equimolar N-acetylcysteine (NAC) followed twenty minutes later by oral (4 ml/kg) administration of APAP (500 mg/kg). A
separate group of animals were given i.p. injections of vehicle followed twenty minutes later by oral administration of APAP. Control mice received an i.p./oral sequence of vehicle injections. Range-finding studies demonstrated that acute i.p. or oral doses of 2-ACP up to 7.2 mmol/kg did not produce gross toxicity or lethality over a 7 day observation period (see also Ballantyne and Cawley, 2001). The doses of NAC used in this study were based on previous published experiments (Corcoran et al., 1985a; Saito et al., 2010). The general health and survival of mice in the different treatment groups was followed by a blinded observer for 7 days post-intoxication. Kaplan-Meier survival curves were used to illustrate the cumulative percent daily lethality of mice in different experimental groups and were generated in Prism 6.0 (Graphpad software). In separate studies, animals were divided according to the previously defined groups (n=15-30/group) and were sacrificed at 2, 6, 24, 48 and 168 hrs after APAP or vehicle administration. At the selected times, mice were anesthetized in a carbon dioxide chamber, decapitated and blood was collected. Livers were excised, weighed and small tissue samples were fixed in 10% phosphate-buffered formalin. Livers were then frozen in liquid nitrogen for later biochemical analyses (see ahead). In subsequent studies, we determined the dose (2-ACP = 0.80-2.40 mmol/kg; NAC = 0.80 - 7.20 mmol/kg)- and route (i.p. vs. oral)-dependent characteristics of the hepatoprotection provided by 2-ACP and NAC in the APAP model. Finally, we determined the temporal characteristics of hepatoprotection; i.e., hepatoprotectant was administered at various times before (-20 mins) or after (+20 or +60 mins) APAP intoxication.

Hepatotoxicity Parameters and Histopathological Analyses. To assess APAP-induced hepatocyte damage, the temporal appearance of the liver-specific enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), in
plasma was measured. In addition, we determined serum levels of lactate dehydrogenase (LDH) as a measure of general cell damage. Blood was collected in heparin-coated tubes (1.5-ml; BD, Franklin Lakes, NJ) and serum samples were obtained by centrifugation (14,000xg for 5 minutes). Samples were subsequently analyzed by an automated analyzer (Hitachi Modular Automated Clinical Chemistry Analyzer; Roche Diagnostics, Indianapolis, IN) and expressed as U/L plasma.

As indices of hepatocyte oxidative stress, soluble thiols and the aldehyde by-products of lipid peroxidation, 4-Hydroxy-2-nonenal (HNE) and malondialdehyde (MDA), were measured in liver homogenates at several time-points (2-168 hrs) following APAP intoxication or vehicle administration. For aldehyde measurements, frozen livers were pulverized and samples (2gm) were added to 2.5ml of radio-immunoprecipitation assay (RIPA) buffer containing protease inhibitor cocktail and butylated hydroxytoluene (BHT; 5mM). Tissue samples were homogenized in a Dounce tissue grinder (10 strokes) and the homogenate was centrifuged at 500xg (4°C) for 15 mins to remove cellular debris. The pellet was washed once in RIPA buffer (2.5ml) and the supernatant (S2) combined with the S1 supernatant. Aldehyde concentrations were determined in aliquots of liver homogenates (1mg protein) by the spectrophotometric method of Gerard-Monnier et al. (1998). Briefly, an aliquot of sample (200μl) was added to 650 μl of 1-methyl-2-phenylindole in an acetonitrile/methanol (3:1) mixture. The reaction was started by adding 150 μl of 12N hydrochloric acid. Absorbance (586 nm) was measured after incubation of the reaction mixture at 45° C for 60 min. The final absorbance was used to determine MDA concentrations (extinction coefficient = 110000 M⁻¹cm⁻¹) based on a standard curve for 1,1,3,3-tetramethoxypropane (TMP; a source of MDA). To determine the respective HNE concentrations, parallel samples (200μl) were added to the 1-
methyl-2-phenylindole mixture and the reaction was started by adding 150 μl of methanesulfonic acid (37%) containing 100 μM Fe(III). Absorbance (586 nm) was measured after incubation at 45°C for 60 min. The final absorbance is a linear function of both the HNE and MDA concentrations and, therefore, the HNE content can be derived by subtracting the previously determined MDA concentration from the combined unsaturated aldehyde content.

To measure sulfhydryl contents in liver supernatants, hepatocyte proteins were precipitated (1:1 v/v methanol/acetonitrile) and then removed by centrifugation at 13,000g (4°C) for 15 mins. This procedure simplifies the analyzate and preserves acid-labile NAPQI-sulfhydryl adducts on proteins and small molecular weight thiol molecules (Gerard-Monnier et al., 1998; Hou et al., 2004). Methanol/acetonitrile-soluble sulfhydryl contents were measured by a colorimetric method using 5,5’-Dithiobis-2-nitrobenzoic acid (DTNB) as previously modified by LoPachin et al. (2009). Data are expressed as μmoles/mg protein ± SEM. In groups of control mice (n=3/time-point) that received an i.p./oral sequence of vehicle injections (see above), the thiol and unsaturated aldehyde parameters were measured on a temporal basis (2-168 hrs). For each parameter, the respective control data among individual time-points did not differ statistically and were therefore pooled.

For histological analyses, liver samples were excised from mice in all experimental groups at the 24 hr post-APAP time-point. Samples were fixed in 10% buffered formalin solution, paraffin embedded, sectioned (5μm) and stained with Hematoxylin and Eosin. Sections were examined by a blinded observer for evidence of inflammation, fatty changes and hepatocellular necrosis, nuclear pleomorphism and vacuolization.
In Chemico Studies Initial in chemico studies determined the relative concentration-dependent abilities of selected quinone and α,β-unsaturated carbonyl derivatives to deplete GSH sulfhydryl groups (Table 1). Graded concentrations (2-128μM; 8μM-1.6M) of electrophile were incubated (15 mins) in phosphate buffered saline (PBS; pH 7.4, 25° C) with GSH (30 μM). At the end of the incubation period, remaining sulfhydryl content was measured spectrophotometrically via the 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) method of LoPachin et al. (2009). To assess the concentration-dependent ability of 2-ACP to prevent thiol loss (Fig. 10), graded NAPQI concentrations (2-128μM) were incubated (15 mins) in PBS (pH 7.4, 25° C) with different concentrations of 2-ACP (25-200 μM). At the end of the pre-incubation period, GSH (30 μM) was added and sulfhydryl content was measured after 15 mins via the DTNB method of LoPachin et al. (2009). Thiol data were fitted by nonlinear regression analyses (r² for all curves ≥ 0.90) and electrophile concentrations that produced 50% thiol loss (IC₅₀'s) and their 95% confidence intervals were calculated by the Sigmoidal Dose-Response equation (variable slope; GraphPad Prism).

Calculations of HSAB Parameters The Lowest Unoccupied Molecular Orbital (LUMO) energy (E_LUMO) and Highest Occupied Molecular Orbital (HOMO) energy (E_HOMO), were determined using Spartan08 (version 1.1.1) software (Wavefunction Inc., Irvine CA). For each structure, ground state equilibrium geometries were calculated with Density Functional B3LYP 6-31G* in water starting from 6-31G* geometries. Global (whole molecule) hardness (η) was calculated as η = (E_LUMO-E_HOMO)/2 and softness (σ) was calculated as the inverse of hardness (i.e., σ= 1/η). The electrophilicity index (ω) was calculated as ω = µ²/2η, where µ is chemical potential of the electrophile.
\( \mu = (E_{\text{LUMO}} + E_{\text{HOMO}})/2 \). An index of nucleophilicity \((\omega, \text{see LoPachin et al., 2012 for more detailed discussion})\) was calculated as \( \omega^- = \eta_A(\mu_A - \mu_B)^2/2(\eta_A + \eta_B)^2 \), where A = reacting nucleophile and B = NAPQI \((\mu = -5.235 \text{ ev}, \eta = 2.005 \text{ ev})\).

**Statistical Analyses** All statistical analyses were conducted using Prism 6.0 (GraphPad software; San Diego, CA) with significance set at the 0.05 level of probability. In studies evaluating the relative abilities of potential hepatoprotectants to modify APAP lethality, the Mantel-Cox log-rank test was used to compare survival rates among the experimental groups. For analysis of liver enzymes in serum and oxidative stress parameters, statistically significant differences between group mean data were determined by a Bonferroni test for multiple comparisons. IC\(50\) values for electrophiles in the *in chemico* studies were compared statistically by Student’s t test.

**Results**

**Effects of i.p. 2-ACP or NAC on Oral APAP-Induced Lethality.** The Kaplan-Meier survival curves presented in Figure 2 demonstrate that mice in the APAP only and the APAP/NAC treatment groups followed a similar cumulative rate of lethality. Specifically, in both groups approximately 10-20% of mice died within the first 24 hrs (day 1) after acute oral APAP administration. In contrast, all mice in the i.p. 2-ACP treatment group survived during this initial period. Over the next 24 hr period (day 2), substantial cumulative lethality was noted in both the APAP-intoxicated (62% lethality) and NAC/APAP (55% lethality) groups, whereas in the 2-ACP treatment group lethality was limited to a single death (97%). By day 3, mice continued to die in both the APAP-intoxicated and NAC/APAP group (~85% cumulative lethality). However, no additional deaths occurred in the 2-ACP-treatment group. Figure 2 shows that, over the next 96
hrs (days 4-7), the percent survival in all groups remained constant. Statistical analyses of the respective survival curves revealed that 2-ACP provided nearly complete protection against the hepatotoxic effects of oral APAP, whereas i.p. administration of NAC failed to produce significant protection.

Effects of Protectants on APAP-Induced Changes in Hepatocyte Biomarkers. The lethality associated with APAP intoxication (Fig. 2) corresponded to the progressive derangement of both serum biomarkers (ALT, AST and LDH) and indicators of oxidative stress (aldehyde accumulation and thiol loss). During the initial 2 hrs post-APAP intoxication, serum biomarker levels rose slowly (Fig. 3A-C). Thereafter, biomarker activity increased rapidly and, at the 24 time-point, the mean peak levels achieved were remarkably elevated indicating significant hepatocyte damage (Agarw et al., 2012; Jaeschke, 1990) e.g., mean (± SEM) 24 hr AST levels were 18,100 ± 3,300 U/L, which represents more than a 110-fold increase relative to the pooled control; 160 ± 20 U/L (Fig. 3A). At 48 hrs (day 2), mean serum biomarker levels decreased by approximately 80% relative to 24 hr values in surviving mice of the APAP-only group (Fig 4A-C). The return toward control values likely reflects pooled measurements of those animals that will survive combined with those that will succumb by day 3. At the 168 hr or 7 day experimental period, mean ALT levels were not different from control, whereas AST and LDH levels were slightly elevated relative to the pooled control data (Fig. 4A-C).

2-ACP injected i.p. twenty mins prior to oral APAP intoxication (-20 min) prevented the APAP-induced serum changes in hepatic biomarkers. For example, the 2-ACP pretreatment group exhibited an initial (2 hrs), relatively small but significant
increase in mean AST compared to control (i.e., 970 ± 130 U/L vs 160 ± 20 UL, respectively). Over the 6 – 48 hr experimental time-points, AST serum levels remained constant at approximately 500-700 U/L, whereas at the 168 hr time-point AST level decreased to 220 ± 25 (Figs. 3B and 4B). In contrast, although NAC pretreatment slowed the APAP-induced rise in serum biomarkers up to 6 hrs post-APAP intoxication, the corresponding 24 hr data were not statistically different from that of the APAP-alone group (Fig. 3A-C). The 48-168 hr serum biomarker data (Fig. 4A-C) for the NAC/APAP group did not differ statistically from that of the APAP-alone group data.

With respect to liver aldehyde concentrations in APAP-treated mice, HNE (Fig. 5A) and MDA (Fig. 5B) increased substantially at 2hrs and then continued to rise slowly over the next 22 hrs. The hepatic thiol content of APAP-intoxicated mice exhibited a similar temporal pattern; i.e., early decreases at 2 hrs followed by continuous slow thiol loss up to the 24 hr time-point (Fig. 5C). Over the 48-168 hr experimental period, the liver thiol and aldehyde concentrations of surviving animals returned toward control values (data not shown). Pretreatment (-20) with i.p. 2-ACP (2.4mmole/kg) substantially modified the APAP-induced changes in liver parameters. Thus, 2-ACP significantly reduced the initial (2hr) increase in mean HNE (Fig. 5A) and MDA (Fig. 5B) concentrations and, by 6 hrs post-APAP aldehyde levels returned to control values. In contrast, NAC did not alter the initial (2 hr) rise in mean HNE (Fig. 5A) or MDA (Fig. 5B), but did significantly reduce the mean 6 hr data. At 24 hrs post-APAP administration, mean liver HNE (Fig. 5A) and MDA (Fig. 5B) values in 2-ACP pretreated animals remained similar to control, whereas in the NAC treated group aldehyde levels were increased (Fig. 5A and B).
With respect to APAP-induced thiol loss (Fig. 5C), 2-ACP pretreatment did not modify early (2 hr) thiol depletion. However, like the aldehydes, thiol levels were similar to control by the 6 hr time-point. NAC pretreatment also did not alter the initial decline in soluble thiol levels and, despite returning toward control values at 6 hrs, by 24 hrs significant thiol loss was noted (Fig. 5C). During the 48-168 hr experimental period, the liver thiol and aldehyde concentrations returned toward control values in surviving animals of the 2-ACP and NAC pretreatment groups (data not shown).

**Histopathology.** The liver histopathological changes noted in the different treatment groups corroborated the corresponding changes in the respective hepatic biomarkers. As expected, all sections from the control group exhibited unremarkable liver histology; i.e., necrosis and steatosis were not observed (Fig. 6A). Liver sections from the 24 hr APAP-only group demonstrated marked hepatocellular necrosis surrounding the central veins (Zone 3) and exhibited frequent bridging necrosis (Fig. 6B). In addition, a significant amount of microvesicular steatosis ranging from moderate to severe was observed. The morphologic pattern and degree of hepatocellular injury associated with APAP intoxication were indistinguishable from level of tissue injury in the NAC-pretreated group (Fig. 6C). In contrast, the 2-ACP pretreatment group showed near-complete protection of hepatocytes (Fig. 6D).

**Route, Dose and Temporal Characteristics of 2-ACP Hepatoprotection.** The findings presented in Fig. 2 indicated that i.p. injection of 2-ACP (2.4mmole/kg) given 20 minutes prior (-20) to an oral overdose of APAP (500 mg/kg) can completely prevent subsequent hepatotoxicity. In contrast, i.p. pretreatment with an equimolar dose of NAC did not provide protection. Dose-dependent analyses (Fig. 7A) showed
that, although i.p. administration of 2-ACP at 0.8 mmole/kg was not protective, the 1.6 mmole/kg dose provided protection that was equivalent to that produced by the 2.4 mmol/kg dose. However, i.p. NAC pretreatment over a broad dose-range (4.8-7.2 mmol/kg) did not provide any level of hepatoprotection (Fig. 7B). In fact, the higher i.p. NAC doses (4.80 and 7.20 mmol/kg) significantly accelerated the APAP lethality rate.

To determine the temporal characteristics of hepatoprotection, 2-ACP or NAC was injected i.p. at selected times after oral APAP intoxication. Results (Fig. 8A) show that 2-ACP (2.4mmol/kg) administered i.p. 20 minutes before (-20 mins) or after (+20 mins) APAP provided significant hepatoprotection, whereas equimolar administration after 60 minutes (+60 group) was completely ineffective. Relative to 2-ACP, i.p. NAC administration exhibited the opposite temporal relationship of hepatoprotection (Fig. 8B); i.e., the +60 NAC group exhibited modest protection, whereas +20 administration did not prevent APAP hepatotoxicity.

To evaluate the route-dependency of hepatoprotection, equimolar doses (2.4mmole/kg) of 2-ACP or NAC were administered by oral gavage 20 minutes prior (-20 groups) to APAP overdose. Results (Fig. 9A) show that NAC pretreatment provided nearly complete protection against APAP hepatotoxicity, whereas 2-ACP was only modestly protective. This decreased effectiveness is likely related to the susceptibility of β-diketones to acid-catalyzed reactions (e.g., aldol condensation) that can occur in the stomach. In support of this, we found that buffering the gavage solution (HEPES buffer, pH 9.0) or increasing the dose (4.80 mmol/kg) improved oral 2-ACP hepatoprotection (data not shown). Evaluation of dose-dependency (Fig. 9B) revealed that the 2.4 mmol/kg and 1.6 mmol/kg NAC doses produced equivalent hepatoprotection, whereas the 0.8mmole/kg dose was ineffective (Fig. 9B).
Mechanism of 2-ACP Hepatoprotection. The active APAP metabolite, NAPQI, is an electrophile and therefore we propose that 2-ACP provides hepatoprotection by acting as a surrogate nucleophile target for this metabolite (Fig. 11). Electrophilic toxicants, however, do not react arbitrarily with nucleophiles, and instead, these interactions are selective as predicted by the Hard and Soft, Acids and Bases (HSAB) theory. Thus, based on relative polarizability (electron mobility), electrophiles and nucleophiles are classified as being either soft (polarizable) or hard (non-polarizable). In accordance with HSAB principles, toxic electrophiles will react preferentially with nucleophilic biological targets of comparable softness or hardness. The designation of “hard” or “soft” is quantifiable based on corresponding inherent electronic characteristics that can be computed from the energies of the respective frontier molecular orbitals; i.e., the Highest Occupied Molecular Orbital (E_HOMO) and the Lowest Unoccupied Molecular Orbital (E_LUMO). These energies have been used to develop parameters that define the electrophilicity (ω) and nucleophilicity (ω') of chemical species (reviewed in LoPachin et al., 2012; LoPachin and Gavin, 2012). Table 1 shows that NAPQI and related quinones are in general exceptionally soft, highly electrophilic chemicals (larger σ and ω values), whereas acrolein and other selected toxicologically relevant α,β-unsaturated carbonyl derivatives exhibit a significantly lower range of softness and electrophilicity (see also LoPachin et al., 2007a,b, 2009). As a soft electrophile, NAPQI will rapidly form covalent adducts with soft nucleophilic sulphydryl groups (e.g., see Dietze et al., 1997; Gibson et al., 1996; Hoffmann et al., 1985; Madsen et al., 2007). This reaction is reflected in the correspondence of the respective IC_{50} values for GSH loss among chemicals with varying electrophilicity (Table 1). The relative nucleophilicity (ω') of 2-ACP and other putative cytoprotectants can also be calculated. Data presented in Table 2 show that,
as a carbon-based nucleophile (ω⁻ value), the enolate of 2-ACP is comparable to the respective nucleophilic thiolate forms of NAC and GSH (for detailed discussions see LoPachin et al., 2012; LoPachin and Gavin, 2012). However, due to a lower pKₐ value, the 2-ACP enolate will be present in significantly higher concentrations than either thiolate at physiological conditions. To determine whether the enolate is capable of cytoprotection through electrophile scavenging, the adduct reaction between NAPQI and a nucleophilic target (GSH) was studied experimentally. Results (Fig. 10) show that NAPQI produced a graded decrease in GSH-derived sulfhydryl groups (IC₅₀ = 9.1μM) and that the addition of 2-ACP prevented this sulfhydryl loss in a concentration-dependent manner; i.e. 2-ACP progressively increased the NAPQI IC₅₀ (Fig. 10). Thus, the relative cytoprotective ability of 2-ACP is determined by the aqueous ionization efficiency (low pKₐ value) and the inherent nucleophilic strength (high ω⁻) of the resulting enolate (see Discussion).

Discussion

We have proposed that β-diketones such as 2-ACP provide cytoprotection through their ability to form nucleophilic enolates. This supposition was based on the recognition that enol moieties of certain phytopolyphenols (e.g., curcumin) can ionize to form nucleophilic enolates and that these carbanions are important structural components of their well-documented cytoprotective properties. Our initial research demonstrated that 1,3-dicarbonyl enolates were cytoprotective in several in vitro models of electrophile toxicity (LoPachin et al., 2011). In the present study, we have expanded our evaluation of cytoprotection into an animal model of APAP hepatotoxicity. Results
show that an oral APAP overdose (500 mg/kg) administered to mice was nearly 90% lethal within 72 hrs (Fig. 2). However, we found that 2-ACP (2.40 mmol/kg) given i.p. 20 minutes prior to intoxication completely prevented APAP lethality over a 7 day experimental period. Whereas 2-ACP hepatoprotection was dose-dependent (Fig. 7A), pretreatment with i.p. NAC over a broad dose-range (4.80–7.20 mmol/kg) was not protective and instead accelerated the rate of APAP lethality (Fig 7B). Measurements of several biochemical indices of hepatocyte death (Fig. 3-4) and oxidative stress (Fig. 5) suggested that 2-ACP, but not NAC, prevented APAP-induced liver cell death. Histopathological analyses (Fig. 6) confirmed hepatocyte preservation and showed that i.p. pretreatment with 2-ACP prevented the centrilobular necrosis that characterizes APAP hepatotoxicity, whereas i.p. NAC did not stop this damage. Studies designed to determine the temporal dependency of hepatoprotection showed that 2-ACP (2.40 mmol/kg, i.p.) afforded complete protection when administered 20 minutes before (-20) or after (+20) APAP intoxication, whereas the +60 time point was ineffective (Fig. 8A). NAC (2.40 mmol/kg, i.p.) was not protective at either 20 minute (±) time points, although when administered 60 minutes (+60) after APAP, NAC partially improved the survival of intoxicated mice (Fig. 8B; also see Corcoran et al., 1985a). Although pharmacokinetic differences might be involved, the corresponding temporal nature of hepatoprotection could indicate that 2-ACP and NAC block different stages of APAP-induced hepatotoxicity (see ahead).

In contrast to the i.p. route, oral gavage administration of 2-ACP 20 minutes before oral APAP intoxication was modestly protective (Fig. 9A), whereas equimolar oral NAC provided complete protection against APAP-induced lethality (Fig. 9B).
Similar to i.p. 2-ACP (Fig. 7A), oral NAC hepatoprotection was dose-dependent over the same narrow dose-range (Fig. 9B). This dosing characteristic has been reported previously for NAC analogues (Roberts et al., 1998) and suggests a threshold concentration for protection. The route dependency (i.p. vs. oral) of NAC protection is well recognized (Corcoran et al., 1985a; Dickey et al., 2008; Shalansky et al., 2005) and could be a product of pharmacokinetic and/or toxicodynamic attributes. Although both the i.p. or oral routes lead to the hepatic portal system, the relatively rapid absorption and elimination kinetics of the i.p. route (Gibaldi and Perrier, 1974) might render the resulting liver NAC concentration insufficient to provide hepatoprotection or temporally disconnected from the later developing target stage of APAP toxicity (see ahead).

Our initial research demonstrated that 1,3-dicarbonyl compounds could provide protection in several cell culture models of electrophile (acrolein)- and oxidative stress (H₂O₂)-induced cytotoxicity (LoPachin et al., 2011). In the acrolein model, the rank order of cytoprotection was directly related to the differential rates of individual acrolein-dicarbonyl adduct reactions. These second order rates are determined by the enolate nucleophilicity (which affects the rate constant of the reaction) and the pKₐ of the parent dicarbonyl compound (which affects the concentration of the reacting nucleophile). In the H₂O₂ model, we found that metal chelation was an important component of 1,3-dicarbonyl cytoprotection. Thus, compounds (e.g., 1,3-cyclopentanedione) with rigid structures that preclude bidentate metal ion coordination were ineffective in the H₂O₂ model, whereas those compounds with flexible structures and metal chelating abilities (e.g., 2-ACP, AcAc) provided substantial cytoprotection. These data indicate that the hepatoprotective mechanism of the 1,3-dicarbonyls could involve: i) scavenging of toxic
electrophiles, which prevents protein inactivation and changes in cellular redox status, and ii) metal ion chelation, which reduces cellular free radical loads by inhibiting the metal-catalyzed Fenton reaction. These cytoprotective mechanisms, considered within the framework of APAP pathophysiology, suggest that 2-ACP could act at multiple sites within the hepatotoxicity pathway. Specifically, the hepatotoxic mechanism appears to involve rapid biotransformation of APAP to NAPQI, which is followed closely by GSH depletion and protein inactivation via sulfhydryl adduct formation (e.g., see Dietze et al., 1997; Gibson et al., 1996; Hoffman et al., 1985). Many researchers consider these to be originating effects that occur within 1-2 hrs of NAPQI generation and accordingly this “Initial Phase” leads to a NAPQI-independent cascade of irreversible hepatocyte injury. This later developing “Toxic Phase” is characterized by mitochondrial damage, DNA fragmentation and the generation of reactive oxygen/nitrogen species (Agarwal et al., 2011; Bajt et al., 2003, 2011; James et al., 2003; Reid et al., 2005).

Based on the preceding, we hypothesize that 2-ACP acts as a surrogate nucleophilic target for NAPQI (Fig. 11) and thereby prevents APAP hepatotoxicity by blocking development of the initial phase. Whereas hepatoprotection might involve inhibition of APAP metabolic activation, we found early (2hr) transient changes in the liver aldehyde and thiol contents of 2-ACP pretreated APAP intoxicated mice (Fig. 5) that were consistent with NAPQI-mediated toxicity (Jaeschke et al., 2011, 2012). This suggests ongoing APAP bioactivation with generation of NAPQI, the toxic effects of which are subsequently prevented by 2-ACP scavenging. Our HSAB calculations indicate that NAPQI is a very soft, highly reactive electrophile (Table 1). As a soft electrophile, NAPQI will react preferentially with soft nucleophiles, which in biological
systems are sulfhydryl thiolate groups on specific cysteine residues of cellular proteins (reviewed in LoPachin and Barber, 2006; LoPachin et al., 2008, 2012; LoPachin and Gavin, 2012). With respect to hepatoprotection, the 2-ACP enolate is a soft, relatively strong carbanion nucleophile with a pKₐ close to physiological pH (Table 2). Accordingly, our *in chemico* studies (Fig. 10) demonstrated that 2-ACP could adduct NAPQI and thereby prevent GSH loss. Although the thiolate of GSH is also a strong nucleophile, due to the relatively high (8.6) pKₐ the majority (94%) of this sulfhydryl species will be present in the non-reactive thiol state (see also LoPachin et al., 2007a,b, 2009). That 2-ACP can scavenge NAPQI and thereby prevent the initiating stage of hepatotoxicity is suggested by the narrow temporal window of in vivo hepatoprotection; i.e., protection at ± 20 mins, but not +60 mins (Fig. 8A). This is consistent with the observation that 2-ACP cannot trap free radicals (LoPachin et al., 2011) and therefore would not directly affect the cellular burden of reactive oxygen/nitrogen species during the later developing toxic phase. Nonetheless, iron-catalyzed free radical formation during this second stage (e.g., see Kon et al., 2010) might be suppressed by the ability of 2-ACP to chelate metal ions, which would contribute to overall hepatoprotection.

In contrast to 2-ACP, NAC is a poor target for NAPQI; i.e., although a significant sulfhydryl nucleophile (Table 2), the high pKₐ of NAC (9.6) means that at physiological pH very little (<1%) of the corresponding cysteine sulfhydryl groups will be in the reactive anionic state. Indeed, previous research has suggested that NAC does not scavenge NAPQI and therefore cannot prevent the initial phase. Rather, NAC hepatoprotection might involve an alternative mechanism that impacts the toxic phase; e.g., free radical trapping, increased GSH synthesis or enhanced mitochondrial energy
production (Corcoran et al., 1985b; Lauterburg et al., 1983; Saito et al., 2010; Zwingmann and Bilodeau, 2006; reviewed in De Flora et al., 2001). Our observation that i.p. NAC provided protection only at 60 mins after APAP is consistent with such a delayed hepatoprotective mechanism (Fig. 8B; see also Corcoran et al., 1985a).

The present study has shown that 2-ACP can provide significant protection in an animal model of APAP poisoning. The anionic enolate of this 1,3-dicarbonyl is a soft nucleophile that can form 1,4-Michael adducts with soft electrophiles of different chemical classes; e.g. quinones, \(\alpha,\beta\)-unsaturated carbonyl/aldehyde derivatives. Our HSAB calculations and \textit{in chemico} studies indicate that 2-ACP can scavenge NAPQI and thereby prevent the initial phase of APAP hepatotoxicity. Although unlikely to be a singular treatment for APAP poisoning in humans, a potentially effective approach might be a combination of 2-ACP and NAC, since this mixture would impact both phases of toxicity. In this regard, it is noteworthy that the 1,3-dicarbonyl compounds are chemically stable, relatively water-soluble compounds that are rapidly absorbed and have large volumes of distribution (Ballantyne and Cawley, 2001; LoPachin et al., 2011). Furthermore, the acute animal toxicity of these chemicals is low (LD\(_{50} > 800\) mg/kg) and longitudinal dosing studies indicate a low incidence of systemic toxicity (e.g., 400-600 mg/kg/d x 60d; Ballantyne and Cawley, 2001; LoPachin et al., unpublished). The mechanism of cytoprotection suggests that the 1,3-dicarbonyls might be useful in the treatment of other drugs that produce toxicity via electrophilic intermediates; e.g., diclofenac, cyclophosphamide, valproic acid (Erve, 2006). In addition, enolate cytoprotection could stem the toxicity of drugs that are significant electrophiles; e.g., cisplatin, clopidogrel (Singh et al., 2011; Wang et al., 1996). This suggestion is feasible,
since electrophile-mediated toxicity can often be prevented without affecting the therapeutic (e.g., antineoplastic) efficacy of these drugs (Borch et al., 1980; Neuwelt et al., 2004). Finally, many environmental chemicals are electrophiles (e.g., acrolein, acrylamide, methylmercury) that produce toxicity as a consequence of acute or chronic exposure. The 1,3-dicarbonyl compounds might therefore be useful in treating the acquired toxicities that occur as a result of environmental exposure to these toxicants (LoPachin et al., 2012; LoPachin and Gavin, 2012).

Acknowledgments

The authors would like to express their gratitude to Dr. Allan W. Wolkoff MD, Division of Gastroenterology and Liver Diseases, Albert Einstein College of Medicine, for his helpful comments and guidance. The authors would also like to thank Irene Ostrovsky (Chemistry laboratory, Department of Pathology), Tewolde Yimer and their staff: Anie George, Faina Kremerman, Don Kutsyk, Kseniya Vayner and Aleksandr Yakubov for their analysis of mouse plasma biochemistry.

Authorship Contributions

Participated in research design: LoPachin, Gavin and Zhang

Conducted experiments: Zhang, Geohagen, Liu, Downey

Performed data analysis: Zhang, Geohagen, Liu, Downey

Wrote or contributed to the writing of the manuscript: LoPachin, Gavin, Downey

Performed Molecular Modeling and Structural Computations: Gavin
References


marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain
tumor model.

Payton F, Sandusky P and Alworth WL (2007) NMR study of the solution structure of

Reid AB, Hennings L, Kurten RC, McCullough S, Brock R and Hinson JA (2005)
Mechanisms of acetaminophen-induced hepatotoxicity: role of oxidative stress and
mitochondrial permeability transition in freshly isolated mouse hepatocytes. *J
Pharmacol Exp Ther* **312**: 509-516.

Differential chemoprotection against acetaminophen-induced hepatotoxicity by

acetaminophen hepatotoxicity in mice by glutathione and *N*-acetylcysteine.
*Hepatology* **51**: 246-254.

Shalansky SJ, Pate GE, Levin A. (2005) *N*-Acetylcysteine for prevention of
radiocontrast-induced nephrotoxicity: the importance of dose and route of
administration. *Heart* **91**:997-999.


Weber WM, Hunsaker LA, Gonzales AM, Heynekamp JJ, Orlando RA, Deck LM and
Vander Jagt DL (2006) TPA-induced up-regulation of activator protein-1 can be

Footnotes

The research described in this manuscript was supported by an NIH grant from the National Institute of Environmental Health Sciences (RO1 ES003830-25).
Figure Legends

Figure 1  Line structures and ionization of 1,3-dicarbonyl compounds.  (a) Line structures for acetylacetone, 2-acetylcyclopentanone (2-AC) and curcumin.  (b) Schematic diagram illustrating the existence of 2-ACP as equilibrating keto-enol tautomers.  (c) Schematic diagram showing that, loss of a proton from either the central ("α") carbon in the diketo tautomer of 2-ACP or the hydroxyl group of the enol isomer yields the same resonance-stabilized enolate anion.

Figure 2  Effects of i.p. 2-ACP (2.40 mmol/kg) or equimolar NAC on oral APAP (500 mg/kg)-induced hepatotoxicity in mice (n = 15-30/group).  Kaplan-Meier survival curves illustrate the cumulative percent daily lethality in the APAP alone, APAP/NAC and APAP/ACP groups.  Joining line indicates statistically significant differences in treatment groups at *** p<0.001 level of significance.

Figure 3  Effects of i.p. 2-ACP (2.40 mmol/kg) or equimolar NAC on the time course (< 24 hrs) for the plasma appearance of lactate dehydrogenase (LDH) and the liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), in APAP-intoxicated mice (n = 15/group) of the different experimental groups.  Data are expressed as mean activity ± SEM and ** p<0.01 and * p<0.05 indicate levels of significance relative to APAP alone group.

Figure 4  Effects of i.p. 2-ACP (2.40 mmol/kg) or equimolar NAC on the time course (48-168 hrs) for the plasma appearance of lactate dehydrogenase (LDH) and the liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), in APAP-intoxicated mice (n = 15/group) of the different experimental groups.  Data are expressed as mean activity ± SEM and ** p<0.01 and * p<0.05 indicate levels of significance relative to the vehicle-treated control.
Figure 5 Effects of i.p. 2-ACP (2.40 mmol/kg) and equimolar NAC on oral APAP (500 mg/kg)-induced changes in 4-hydroxy-2-nonenal (A. HNE), malondialdehyde (B. MDA) and soluble thiol (C.) content in mouse liver homogenates (n = 10/group). Data are expressed as mean μmoles/mg ± SEM and * p<0.05 indicates the level of significance relative to the APAP alone group.

Figure 6 Representative photomicrographs showing the effects of i.p. 2-ACP (2.40 mmol/kg) and equimolar NAC on oral APAP (500 mg/kg)-induced histopathological changes in mouse liver. Tissue was excised at 24 hrs post-APAP intoxication, fixed and then stained with hematoxylin and eosin. Magnification, x200.

Figure 7 (A). Dose-dependency of i.p. 2-ACP (0.80 – 2.40 mmol/kg) on oral APAP (500 mg/kg)-induced lethality. (B). Dose-dependency of i.p. NAC (2.40 – 7.20 mmol/kg) on oral APAP-induced lethality. Kaplan-Meier survival curves illustrate the cumulative percent daily lethality in the APAP alone, APAP/NAC and APAP/ACP groups (n= 15 mice/group). Joining line indicates statistically significant differences in treatment groups at *** p<0.001 and **p<0.01 levels of significance.

Figure 8 Temporal-dependency of i.p. 2-ACP (A. 2.40 mmol/kg) or equimolar NAC (B) on oral APAP (500 mg/kg)-induced lethality. Hepatoprotectants were administered 20 mins before (-20), 20 mins after (+20) or 60 mins after (+60) APAP intoxication. Kaplan-Meier survival curves illustrate the cumulative percent daily lethality in the APAP alone, APAP/NAC and APAP/ACP groups (n= 15 mice/group). Joining line indicates statistically significant differences in treatment groups at ** p<0.01 and *p<0.05 levels of significance.

Figure 9 (A). Effects of oral 2-ACP (A. 2.40 mmol/kg) or equimolar NAC on oral APAP (500 mg/kg)-induced lethality. (B). Dose-dependency of oral NAC (0.80 - 2.40 mmol/kg)
on oral APAP (500 mg/kg)-induced lethality. Kaplan-Meier survival curves illustrate the cumulative percent daily lethality in the APAP alone, APAP/NAC and APAP/ACP groups (n= 15 mice/group). Joining line indicates statistically significant differences in treatment groups at *** p<0.001 and *p<0.05 levels of significance.

**Figure 10** To assess the concentration-dependency of 2-ACP thiol protection, graded NAPQI concentrations (2-128 μM) were incubated (15 mins) with different concentrations of 2-ACP (25-200 μM). At the end of the pre-incubation period, GSH (30 μM) was added and sulfhydryl content was measured after 15 mins by the DTNB method. Data are expressed as mean percent control ± SEM (n = 3-4 experiments). Calculated IC₅₀s are provided in parentheses.

**Figure 11** Schematic diagram showing cytochrome P450 (P450) metabolism of acetaminophen to the electrophilic metabolite, NAPQI, and the subsequent adduct-forming reactions with the enolate of 2-ACP or the GSH thiolate.
Table 1. Softness, Electrophilicity and IC\textsubscript{50} Values for Quinone and \(\alpha,\beta\)-Unsaturated Carbonyl Derivatives

Softness (\(\sigma\)) and electrophilicity (\(\omega\)) for the selected compounds were calculated as described in the Materials and Methods section. The respective IC\textsubscript{50} values represent \textit{in vitro} electrophile concentrations that produce 50% thiol loss and reflect the relative electrophilic potency of each chemical. Abbreviations: NAPQI - N-acetyl-p-benzoquinamide; pBQ, benzoquinone; tBQ, 2-\textit{tert}-butyl-1,4-benzoquinone; HNE – 4-hydroxy-2-nonenal.

<table>
<thead>
<tr>
<th>Electrophile</th>
<th>(\sigma) (x10\textsuperscript{3} ev\textsuperscript{-1})</th>
<th>(\omega) (ev)</th>
<th>IC\textsubscript{50} ((\mu)M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAPQI</td>
<td>500</td>
<td>6.83</td>
<td>9.1</td>
</tr>
<tr>
<td>pBQ</td>
<td>524</td>
<td>7.78</td>
<td>11.6</td>
</tr>
<tr>
<td>tBQ</td>
<td>505</td>
<td>7.20</td>
<td>17.5</td>
</tr>
<tr>
<td>HNE</td>
<td>393</td>
<td>3.78</td>
<td>ND</td>
</tr>
<tr>
<td>Acrolein</td>
<td>379</td>
<td>3.57</td>
<td>52.5</td>
</tr>
<tr>
<td>Acrylamide</td>
<td>346</td>
<td>2.62</td>
<td>436,515</td>
</tr>
</tbody>
</table>
Table 2. HSAB and Ionization Parameters for Thiolate and Enolate Nucleophiles

Softness (\(\sigma\)) and nucleophilicity (\(\omega^-\); NAPQI as the reacting electrophile) for the selected compounds were calculated as described in the Materials and Methods section. Abbreviations: 2-ACP, 2-acetylcyclopentanone; GSH, glutathione and NAC, N-acetylcysteine

<table>
<thead>
<tr>
<th>Nucleophile</th>
<th>(\sigma) ((x10^{-3}\text{ ev}^{-1}))</th>
<th>(\omega^-) ((x10^{-3}\text{ ev}))</th>
<th>(pK_a)</th>
<th>%Anion (\text{(pH = 7.4)})</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-ACP (enolate)</td>
<td>418</td>
<td>485</td>
<td>7.8</td>
<td>28.5</td>
</tr>
<tr>
<td>GSH (thiolate)</td>
<td>427</td>
<td>548</td>
<td>8.6</td>
<td>5.9</td>
</tr>
<tr>
<td>NAC (thiolate)</td>
<td>367</td>
<td>667</td>
<td>9.5</td>
<td>0.8</td>
</tr>
</tbody>
</table>
Fig. 1

A. 1,3-Dicarbonyl Compounds

acetylacetone 2-ACP curcumin

B. Enolization

1,3-dicarbonyl (β-diketo tautomer) enol tautomer

C. Enolate Formation

β-diketo tautomer → enolate anion → enol tautomer
Fig. 2

![Graph showing percent survival over days elapsed for different treatment groups: APAP/ACP, APAP/NAC, and APAP alone. The graph indicates significantly lower survival in the APAP/ACP group compared to the other groups. The survival rates are marked at 0%, 25%, 50%, 75%, and 100% across the days elapsed axis.]
Fig. 4

(A) ALT
Activity (X 100 U/L)

(B) AST
Activity (X 100 U/L)

(C) LDH
Activity (X 1000 U/L)

Sacrifice time (hr)

Legend:
- APAP alone
- APAP/NAC
- APAP/ACP

** Significant difference
Fig. 5

A  HNE

\[ \text{\textmu{m}} \text{oles/mg} \]

- APAP alone
- APAP/NAC
- APAP/ACP

B  MDA

\[ \text{\textmu{m}} \text{oles/mg} \]

C  Soluble Thiols

\[ \text{moles/mg} \]

Sacrifice time (hr)
Fig. 11

NHCOCH₃

OH

P450

NHCOCH₃

COCH₃

enolate

NCOCH₃

GS⁻

thiolate

NAPQI

OH

SG